Heart Failure in Anthracycline Cardiotoxicity: From Mechanisms to Clinical Management
ESC Heart Failure · 13.11.2026
DOI: 10.1093/eschf/xvag284 ↗Kurz gefasst
Fachartikel in der Zeitschrift ESC Heart Failure, online erschienen am 13.11.2026. Verfasst von Marija M Polovina und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, University Clinical Centre of Serbia, Belgrade, Serbia. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Anthracyclines remain a cornerstone therapy for haematological malignancies and solid tumours, but their use is limited by cardiotoxicity, ranging from asymptomatic left ventricular dysfunction to overt heart failure (HF). The risk increases with cumulative doxorubicin-equivalent exposure exceeding 250–300 mg/m2, although susceptibility varies substantially according to patient characteristics, pre-existing cardiovascular disease, genetic predisposition, and modifiable risk factors. Clinically overt HF occurs in ∼6–9% of patients, while subclinical cardiac dysfunction develops in up to 18%. The pathophysiology is multifactorial, involving interconnected mechanisms that disrupt cardiomyocyte homeostasis and promote endothelial dysfunction, inflammation, fibrosis, and adverse remodelling. Yet evidence connecting molecular mechanisms with long-term HF outcomes in humans remains incomplete. Risk stratification, incorporating clinical variables, cardiac biomarkers, echocardiography and, when appropriate, cardiac magnetic resonance enables earlier recognition of cardiac dysfunction. Trials of preventive neurohormonal treatment and statins have produced heterogeneous results, often relying on imaging rather than clinical HF endpoints. Once cardiac dysfunction develops, prompt initiation of foundational HF treatment and multidisciplinary decisions on cancer therapy are essential. Early detection and prompt initiation of HF therapies may reverse myocardial dysfunction, whereas delayed recognition is associated with a poorer treatment response and prognosis. This narrative review integrates current evidence on the mechanisms, risk stratification, surveillance, prevention, and management of anthracycline cardiotoxicity and HF, while highlighting gaps in knowledge, emerging therapeutic strategies, and future directions for clinically meaningful, risk-guided research.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, University Clinical Centre of Serbia, Belgrade, Serbia.
- Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
- Center for Medical Biochemistry, University Clinical Centre of Serbia, Belgrade, Serbia.
- Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
- Emergency Institute for Cardiovascular Diseases Prof. C.C. Iliescu; University of Medicine Carol Davila, Bucharest, Romania.
- University Hospital Medical Centre Bežanijska Kosa, Belgrade, Serbia.
ORCID-Profile: Marija M Polovina, Magdy Abdelhamid, Marianna Adamo, Ovidiu Chioncel, Gianluigi Savarese
Zitieren
APA
Polovina, M. M., Viduljević, M., Tomić, M., Stanković, S., Krljanac, G., Geavlete, O., Zdravković, M., Abdelhamid, M., Adamo, M., Chioncel, O., Savarese, G., & Seferović, P. M. (2026). Heart Failure in Anthracycline Cardiotoxicity: From Mechanisms to Clinical Management. ESC Heart Failure. https://doi.org/10.1093/eschf/xvag284
Vancouver
Polovina MM, Viduljević M, Tomić M, Stanković S, Krljanac G, Geavlete O, et al. Heart Failure in Anthracycline Cardiotoxicity: From Mechanisms to Clinical Management. ESC Heart Failure. 2026. doi:10.1093/eschf/xvag284
BibTeX
@article{Polovina2026,
author = {Polovina, Marija M and Viduljević, Mihajlo and Tomić, Milenko and Stanković, Sanja and Krljanac, Gordana and Geavlete, Oliviana and Zdravković, Marija and Abdelhamid, Magdy and Adamo, Marianna and Chioncel, Ovidiu and Savarese, Gianluigi and Seferović, Petar M},
title = {Heart Failure in Anthracycline Cardiotoxicity: From Mechanisms to Clinical Management},
journal = {ESC Heart Failure},
year = {2026},
doi = {10.1093/eschf/xvag284}
}
EUVIMED